Antisense oligonucleotides (ASOs) are a powerful platform capable of regulating the expression of not only mRNA but also all types of RNA. Liid Pharmaceuticals is committed to advancing the development of ASOs, particularly through the innovative BROTHERS (BRO) technology, which enhances the therapeutic potential of ASOs by expanding their efficacy and safety profiles through non-equilibrium thermodynamics. With a strong focus on central nervous system (CNS) disorders, Liid Pharmaceuticals is actively developing a diverse pipeline to address unmet medical needs and contribute to the future of precision medicine.